Finance Watch: Q4 Venture Financings Slumped But 2024 Outlook Is Optimistic

New Year Begins With New Funds, New Deals

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.

Finance Watch Private Company
• Source: Shutterstock

Venture capital fundraising by biopharmaceutical companies plunged in the fourth quarter to $4.3bn, down from $6.2bn in the third quarter and below the $5.7bn raised in Q4 of 2022, according to the latest Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA). Full-year 2023 funding fell to $18.4bn, down from $24.5bn in 2022 for US-based companies.

The Pitchbook/NVCA numbers track with the most recent venture capital data tabulated by Evaluate, which showed $3.71bn raised globally in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.